All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2014-002254-40 | A phase 2, double-blind, dose-finding, placebo-controlled study to assess the safety and efficacy of a single oral administration of OBE001 to improve embryo implantation following IVF or ICSI. | 2016-11-29 | due-trials |
Reported results | 2014-003217-28 | A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened ... | 2016-10-28 | due-trials |
Reported results | 2016-001736-35 | A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain. | 2019-09-04 | due-trials |
Reported results | 2016-004059-53 | A Phase 3, multicentre, randomized, double-blind, placebo controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy ... | 2020-11-09 | due-trials |
Reported results | 2016-004266-25 | A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 a... | 2019-02-19 | due-trials |
Ongoing | 2017-002579-25 | A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of OBE022 added-on to atosiban, after oral administ... | not-yet-due | |
Completed, but no date, and reported results | 2017-004042-14 | An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis. | bad-data | |
Completed, but no date, and reported results Terminated | 2017-004043-21 | An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis. | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2018-002910-11 | A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to increase ongoing pregnancy rate following fresh single b... | 2020-11-19 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2019-000283-26 | A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain. | 2022-06-28 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2019-002410-39 | A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain. | 2022-12-16 | bad-data |
Listed as ongoing, but also has a completion date and reported results | 2021-000452-19 | A long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix, PRIMROSE 1 or PRIMROSE 2 | 2022-11-14 | bad-data |